We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Two Serodiagnostic Tests Compared for Loiasis in Non-Endemic Area

By LabMedica International staff writers
Posted on 18 Jun 2020
Loiasis, the disease caused by the infection with the filarial nematode Loa loa, is transmitted through the bite of tabanid flies of the genus Chrysops. More...
It is endemic in Central and West Africa where, according to the most recent estimates, about 10 million people are infected.

There is a scarcity of convenient, commercial diagnostics for L. loa. Microscopy requires trained personnel and has low sensitivity, while the serodiagnosis is currently not standardized. Individual case management is also important in non-endemic countries to treat migrants, expatriates and tourists.

Scientists at the Sacro Cuore Don Calabria Hospital (Verona, Italy) retrospectively compared the performance of an Antibody Rapid Test (RDT) and a commercial ELISA pan-filarial test on 170 patients, 65 with loiasis [8 with eyeworm, 29 with positive microfilaremia, 28 with neither microfilaremia nor history of eyeworm but eosinophilia and history of Calabar swelling (probable loiasis)], 95 with other common parasitic infections and no previous exposure to L. loa (37 with M. perstans, one with Brugia sp., 18 with strongyloidiasis, 20 with schistosomiasis, five with hookworm, four with Ascaris lumbricoides infection, 10 with hyper-reactive malarial splenomegaly), and 10 uninfected controls.

The Loa Antibody Rapid Test (RDT, Drugs & Diagnostics for Tropical Diseases, San Diego, CA, USA) detects human IgG against a 148-aminoacid sequence of Ll-SXP-1, a protein with 51–53% sequence identity with Wuchereria bancrofti and Onchocerca volvulus, the two most clinically relevant filarial species. The commercial ELISA kit uses Acanthocheilonema viteae antigens (Bordier Affinity Products, Crissier, Switzerland) and this test is not specific for single filarial species, and detects IgG against various filarial nematodes affecting humans.

The investigators reported that the sensitivity of the RDT and of the ELISA were 93.8% (61/65) and 90.8% (59/65), respectively. For the RDT, most of the cross-reactions were observed in patients with M. perstans: 7/37 (18.9%), followed by 1/10 (10%) with hyper-reactive malarial splenomegaly and 1/20 (5%) with schistosomiasis. None of the 27 subjects infected with intestinal nematodes was found positive with this test. The ELISA is meant to be a pan-filarial assay, and reacted extensively with cases of M. perstans (95%), as expected, and also in 11/18 (61.1%) patients with strongyloidiasis and in 3/5 (60%) with hookworm infection.

The authors concluded that the novel lateral flow RDT has proven to be an accurate and user-friendly tool for the diagnosis of L. loa infection. While some cross-reactivity with M. perstans should be taken into account when considering its potential application as a screening tool in endemic areas, on the other hand this new test appears to be promising in the of non-endemic setting, where it could be included in a management algorithm. The study was published on May 26, 2020 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Sacro Cuore Don Calabria Hospital
Drugs & Diagnostics for Tropical Diseases
Bordier Affinity Products



New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The SimpleScreen CRC platform uses multiomics, AI, and machine learning to analyze blood-based signals and detect cancer-associated patterns (Photo courtesy of Freenome)

Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions

Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.